ASH 2021 | The future of next-generation sequencing assays in myeloma treatment
Shankara Anand
• 12 Dec 2021
Shankara Anand, MS, Broad Institute of MIT & Harvard, Cambridge, MA, highlights the need for advances to be made in the use of next-generation sequencing (NGS) assays in a clinical setting, and current challenges with the financial costs of these assays. Mr Anand then discusses the benefit that these sequencing panels could bring to the future of risk stratification models and patient care in myeloma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
